Post-stroke cognitive trajectory according to amyloid depositio

Not Applicable

Conditions: Diseases of the nervous system

Registration Number: KCT0005086

Lead Sponsor: The Catholic University of Korea, Eunpyeong St. Mary's Hospital

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot yet recruiting

Sex: All

Target Recruitment: 196

Inclusion Criteria

1) patients who were diagnosed as mild cognitive impairment within 3 months from acute cerebral infarct
2) aged 60-80
3) cognitive impairments were newly developed or aggravated after cerebral infarct

Exclusion Criteria

1) patient who was diagnosed as dementia before the cerebral infarct
2) other neurological, psychiatric, or medical disease that cause cognitive impairment
3) patient taking a cholinesterase inhibitor within 3 months from baseline
4) strategic infarct or large territory infarct involving cortical areas
5) modified Rankin Scale (mRS) >3
6) patients with aphasia
7) blindness, deafness, or severe language impairment that might be impossible for study evaluations
8) severe liver disease or kidney disease that needs dialysis
9) malignancy that was not completely resolved
10) schizophremia or bipolar disorders (DSM-IV Axis I psychiatric disease)
11) mental retardation
12) history of encephalitis
13) head trauma history that caused loss of consciousness>1 hour
14) history of traumatic intracranial hemorrhage, brain tumor, or subarachnoid hemorrhage
15) abnormality in thyroid function tests
16) vitamin B12 or folate deficiency
17) neurosyphilis
18) history of metabolic encephalopathy

Study & Design

Study Type: Observational Study

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mini-Mental State Examination (MMSE) (0~30)

Secondary Outcome Measures

Name	Time	Method
Montreal Cognitive Assessment (MOCA) (0~30);Modified Rankin scale (mRS) (0~6);NIHSS (National Institutes of Health Stroke Scale) (0~42);clinical dementia rating (CDR) (0~3);global deterioration scale (GDS) (1~7);white matter hyperintensity grading (minimal, moderate, severe);Scheltens' visual rating scale (hippocampal atrophy grade 0~4)